Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | PDE2A | O00408 | 5/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14256893 | 0.80 | MEN1 (0.49) | MEN1KMT2ALMNAALDH1A1MAPK1 | |
| SCHEMBL1758520 | 0.77 | MEN1 (0.41) | MEN1KMT2ALMNAALDH1A1MAPK1 | |
| SCHEMBL1758521 | 0.77 | MEN1 (0.41) | MEN1KMT2ALMNAALDH1A1MAPK1 | |
| SCHEMBL30673508 | 0.76 | MEN1 (0.43) | MEN1KMT2ALMNAALDH1A1MAPK1 | |
| SCHEMBL1457064 | 0.76 | MEN1 (0.43) | MEN1KMT2ALMNAALDH1A1MAPK1 | |
| SCHEMBL30534235 | 0.76 | MEN1 (0.46) | MEN1KMT2ALMNAALDH1A1MAPK1 | |
| SCHEMBL58769 | 0.76 | MEN1 (0.46) | MEN1KMT2ALMNAALDH1A1MAPK1 | |
| SCHEMBL26915295 | 0.76 | PDE2A (0.50) | MEN1KMT2ALMNAALDH1A1MAPK1 | |
| SCHEMBL1758522 | 0.75 | MEN1 (0.40) | MEN1KMT2ALMNAALDH1A1MAPK1 | |
| SCHEMBL171040 | 0.74 | PDE2A (0.50) | MEN1KMT2ALMNAALDH1A1PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080261-A1 | Purine inhibitors of cyclin dependent kinase 2 and IkappaB-alpha | LUM ROBERT T (US) | 2005-04-14 | — | — | US | claimed |
| EP-1150982-B1 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IkB-alpha | CV THERAPEUTICS INC (US) | 2005-10-12 | — | — | EP | disclosed |
| US-6790958-B2 | ANTIPROLIFERATIVE AGENTS; FUNGICIDES | LUM ROBERT T (US) | 2004-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080261-A1 | Purine inhibitors of cyclin dependent kinase 2 and IkappaB-alpha | IKBKB, NFKB1, CDK4 | MEN1 3966/4885KMT2A 382/4885LMNA 1894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.